Paper
Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome
Published Dec 4, 2014 · F. Xu, Q. He, Xiao Li
Scientific Reports
Q1 SJR score
25
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro StudyStudy Snapshot
Rigosertib is a selective anti-tumor agent that can improve multiple dysregulated signaling pathways in high-grade myelodysplastic syndrome.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
Intravenous rigosertib is well-tolerated and has clinical activity in patients with higher risk myelodysplastic syndromes after DNA methyltransferase inhibitor treatment.
2015·51citations·L. Silverman et al.·Hematological Oncology
Hematological Oncology
Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis
The 15 mg/M2/d5 day decitabine regimen is effective and safe for Chinese MDS patients with IPSS score of 0.5 or higher, with 67.1% achieving treatment response and no therapy-related death.
2014·9citations·Xiao Li et al.·PLoS ONE
PLoS ONE
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Oral rigosertib, a dual PI3K and Plk1 pathway inhibitor, shows potential in advanced solid malignancies, with urinary toxicity being the most common toxicity.
2014·54citations·D. Bowles et al.·Clinical Cancer Research
Clinical Cancer Research
The genetic basis of myelodysplasia and its clinical relevance.
Myelodysplastic syndromes (MDSs) are linked to various oncogenic mutations, with specific mutations associated with certain MDS types, highlighting the need for molecular characterization in clinical trials.
2013·339citations·M. Cazzola et al.·Blood
Blood
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
Oral rigosertib is bioavailable, well-tolerated, and shows clinical activity in patients with myelodysplastic syndromes.
2013·56citations·R. Komrokji et al.·British Journal of Haematology
British Journal of Haematology
Citations
Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy
Small-molecule CDK inhibitors show promise for effective cancer therapy, with five already approved for treatment of various cancers and others in clinical trials.
2024·0citations·Ya-Tao Wang et al.·Molecules
Molecules
Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
Human-specific physiological nutrient medium can help identify cancer therapeutics whose efficacy may be influenced in humans.
2024·1citation·Vipin Rawat et al.·JCI Insight
JCI Insight
Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
Urinic acid, a uniquely abundant nutrient in humans, may be an uncompetitive inhibitor of rigosertib, potentially explaining its failure in clinical trials.
2023·2citations·Vipin Rawat et al.·bioRxiv
bioRxiv
Rigosertib is more potent than wortmannin and rapamycin against adult T‐cell leukemia‐lymphoma
Rigosertib is more effective than wortmannin and rapamycin in inducing cell cycle arrest and late apoptosis in adult T-cell lymphoblastic leukemia cells, potentially benefiting patients.
2023·1citation·Mohsen Ghorbanzadeh Neghab et al.·BioFactors
BioFactors
Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)
Rigosertib is a multi-target inhibitor with potential clinical implications for treating various cancers, but its mechanism of action remains unclear, hindering its clinical progress.
2023·6citations·Ana Monfort-Vengut et al.·Pharmaceutics
Pharmaceutics
Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent
Rigosertib shows different efficacy depending on the cell line and could be a potential antineoplastic agent against lung cancer in humans.
2023·3citations·A. Malacrida et al.·International Journal of Molecular Sciences
International Journal of Molecular Sciences
Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib
Novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib show potent antitumor activity with nanomolar levels and low toxicity to normal cells, including (2-methoxy-5-((naphthalen-2-y
2021·3citations·Lin Tang et al.·RSC Advances
RSC Advances
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells
Rigosertib shows potential as a therapeutic option for nonresectable cholangiocarcinoma patients, with its antitumoral effects and radiosensitizing effects making it a stronger radiosensitizer than Gemcitabine and 5-Fluorouracil.
2021·4citations·A. Malacrida et al.·International Journal of Molecular Sciences
International Journal of Molecular Sciences